Transgenic mouse expressing the human cyclooxygenase-2 gene and neuronal cell cultures derived therefrom
AssigneeMount Sinai of Medicine of New York University
InventorsGIULIO M. PASINETTI, PAUL S. AISEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of nimesulide and structurally related compounds in the prevention and/or treatment of neurodegenerative conditions. It is based, at least in part, on the discovery that nimesulide exhibits a neuroprotective effect against &bgr.-amyloid induced cell death Without being bound to any particular theory, it appears that nimesulide inhibits a non-inflammatory mechanism of neurodegeneration
Claims15
Use of nimesulide for the preparation of a pharmaceutical composition for treating a neurodegenerative condition.
Use of nimesulide for the preparation of a pharmaceutical composition for treating Alzheimer's Disease.
Use of nimesulide for the preparation of a pharmaceutical composition for treating epilepsy.
Use of nimesulide for the preparation of a pharmaceutical composition for treating amyotrophic lateral sclerosis.
Use of nimesulide for the preparation of a pharmaceutical composition for treating a neurodegenerative condition in a subject, wherein the amount of nimesulide present in the pharmaceutical composition results in exposure of the affected neurons to a local concentration of nimesulide of one micromolar or a lower concentratioin that inibits neuronal cell death by at least 20 percent.
Use of nimesulide for the prepararion of a pharmaceutical composition for treating Alzheimer's Disease in a subject, wherein the amount of nimesulide present in the pharmaceutical composition results in exposure of the affected neurons to a local concentration of nimesulide of one micromolar or a lower concentration that inhibits neuronal cell death by at least 20 percent.
Use of nimesulide for the preparation of a pharmaceutical composition for treating epilepsy in a subject, wherein the amount of nimesulide present in the pharmaceutical composition results in exposure of the affected neurons to a local concentration of nimessulide of one micromolar or a lower concentration that inhibits neuronal cell death by at least 20 percent.
Use of nimesulide for the preparation of a pharmaceutical composition for treating amyotrophic lateral sclerosis in a subject, wherein the amount of nimesulide present in the pharmaceutical composition results in exposure of the affected neurons to a local concentration of nimesuide of one micromolar or a lower concentration that inhibits neuronal cell death by at least 20 percent.
A transgenic mouse carrying a gene encoding the human cyclcoxygenase-2 gene under the control of a neuron-specific promoter.
Use of nimesulide for the preparation of a pharmaceutical composition for treating a neurodegenerative condition, wherein the dosage of nimesulide contained in the pharmaceutical composition inhibits neuronal cell death by at least 20 percent.
Use of nimesulide for the preparation of a pharmaceutical composition for treating Alzheimer's Disease, wherein thc dosage of nimesulide contained in the pharmaceutical composition inhibits neuronal cell death by at least 20 percent.
Use of nimesulide for the preparation of a pharmaceutical composition for treating epilepsy, wherein the dosage of nimesulide contained in the pharmaceutical composition inhibits neuronal cell death by at least 20 percent.
Use of nimesulide for the preparation of a pharmaceutical composition for treating amyotrophic lateral sclerosis, wherein the dosage of nimesulide contained in the pharmaceutical composition inhibits neuronal cell death by at least 20 percent.
Dependencies are inferred from the claim text.